ALL Blinatumomab Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. IND Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy. IND Dasatinib Geïndiceerd voor de behandeling van volwassen patiënten met: nieuw gediagnosticeerde Philadelphiachromosoom-positieve (Ph+) chronische myeloïde leukemie (CML) in de chronische fase. CML in de chronische, acceleratie- of blastaire fase, die resistent of intolerant zijn voor eerder toegediende geneesmiddelen inclusief imatinib. Ph+ acute lymfoblastaire leukemie (ALL) en lymfoïde blasten CML die resistent of intolerant zijn voor eerder toegediende geneesmiddelen. Ook geïndiceerd voor de behandeling van pediatrische patiënten met: nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib. Nieuw gediagnosticeerde Ph+ ALL in combinatie met chemotherapie. G Geïndiceerd voor de behandeling van volwassen patiënten met: nieuw gediagnosticeerde Philadelphiachromosoom-positieve (Ph+) chronische myeloïde leukemie (CML) in de chronische fase. CML in de chronische, acceleratie- of blastaire fase, die resistent of intolerant zijn voor eerder toegediende geneesmiddelen inclusief imatinib. Ph+ acute lymfoblastaire leukemie (ALL) en lymfoïde blasten CML die resistent of intolerant zijn voor eerder toegediende geneesmiddelen. Ook geïndiceerd voor de behandeling van pediatrische patiënten met: nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib. Nieuw gediagnosticeerde Ph+ ALL in combinatie met chemotherapie. G autologous anti-CD19-transduced CD3+ cells IND AML / MDS Arseentrioxide Geïndiceerd voor het induceren van remissie en consolidatie bij volwassen patiënten met: 1) nieuw gediagnosticeerde acute promyelocytaire leukemie (APL) met laag tot middelmatig risico (aantal witte bloedcellen ≤ 10 x 103/μl) in combinatie met all-trans-retinoïnezuur (ATRA), 2) recidiverende/refractaire acute promyelocytaire leukemie (APL) (tijdens een eerdere behandeling moet een retinoïde stof zijn toegediend en chemotherapie hebben plaatsgehad), gekenmerkt door de aanwezigheid van de translocatie t(15;17) en/of de aanwezigheid van het gen promyeolocitaire-leukemie-/retinoïnezuurreceptor-alfa (PML/RAR-alfa). G Geïndiceerd voor het induceren van remissie en consolidatie bij volwassen patiënten met: 1) nieuw gediagnosticeerde acute promyelocytaire leukemie (APL) met laag tot middelmatig risico (aantal witte bloedcellen ≤ 10 x 103/μl) in combinatie met all-trans-retinoïnezuur (ATRA), 2) recidiverende/refractaire acute promyelocytaire leukemie (APL) (tijdens een eerdere behandeling moet een retinoïde stof zijn toegediend en chemotherapie hebben plaatsgehad), gekenmerkt door de aanwezigheid van de translocatie t(15;17) en/of de aanwezigheid van het gen promyeolocitaire-leukemie-/retinoïnezuurreceptor-alfa (PML/RAR-alfa). G Azacitidine Eprenetapopt Gilteritinib Glasdegib Guadecitabine Idasanutlin Imetelstat Iomab-B Pevonedistat Sapacitabine Venetoclax IND Aggressive non-Hodgkin's lymphoma Axicabtagene ciloleucel IND Ibrutinib IND Lisocabtagene maraleucel MB-CART2019.1 Polatuzumab vedotin Tafasitamab Tagraxofusp Zanubrutinib Bladder cancer Atezolizumab Extension of indication to include, in combination with platinum-based chemotherapy, first-line treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) for Tecentriq. IND Adjuvant treatment after surgical resection of high-risk muscle-invasive bladder cancer (MIBC). IND Avelumab IND Durvalumab IND Enfortumab vedotin Erdafitinib Nivolumab IND Oportuzumab monatox Brain cancer Autologous glioma tumor cell lysates Vocimagene amiretrorepvec Breast cancer Abemaciclib IND Alpelisib Atezolizumab IND Balixafortide Efbemalenograstim alfa Margetuximab Neratinib IND Olaparib IND Paclitaxel Pembrolizumab Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. IND Triple Negative Breast Cancer - Neoadjuvant and adjuvant. IND Pertuzumab / trastuzumab Sacituzumab govitecan Tesetaxel Trastuzumab deruxtecan Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Patients with HER2 low, unresectable, and/or metastatic breast cancer previously treated with 1-2 prior lines of chemotherapy in the metastatic setting and has progressed on, and would no longer benefit from, endocrine therapy. IND Treatment of adult patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane 2L. IND Trastuzumab duocarmazine Trastuzumab emtansine IND Tucatinib CLL Acalabrutinib Calquence as monotherapy is indicated for the treatment of adult patients with relapsed/refractory CLL (chronic lymphocytic leukemia). Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Duvelisib Ibrutinib Extension of indication to the existing chronic lymphocytic leukaemia (CLL) indication to include combination use with obinutuzumab for the treatment of adult patients with previously untreated CLL. IND Extension of indication in chronic lymphocytic leukaemia (CLL) to add combination with rituximab as follows; Ibrutinib in combination with rituximab or obinutuzumab for the treatment of adult patients with previously untreated CLL (Young and Fit). IND Moxetumomab pasudotox Ublituximab Venetoclax IND ibrutinib IND Cervical cancer Cemiplimab IND Lifileucel Colon cancer Eflornithine / sulindac Nivolumab IND Tegafur / gimeracil / oteracil IND Head and neck cancer Durvalumab Squamous cell carcinoma of the head and neck, 1L PDL 1 in combination with tremelimumab. IND Squamous cell carcinoma of the head and neck, 1L PDL 1. IND Leukocyte interleukin Pembrolizumab IND Hodgkin's lymphoma Pembrolizumab IND Indolent non-Hodgkin's lymphoma Axicabtagene ciloleucel IND Copanlisib Ibrutinib Follicular lymphoma (FL), relapsed / refractory. IND Marginal zone lymphoma (MZL), relapsed / refractory. IND Umbralisib Kidney cancer Avelumab IND Cabozantinib IND Lenvatinib IND Pembrolizumab Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy. IND Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC). IND Tivozanib IND Leukemia Asciminib Liver cancer Atezolizumab IND Durvalumab Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. IND In combination with tremelimumab in patients with HCC not eligible for locoregional therapy (1L). IND Pembrolizumab IND Pemigatinib Tremelimumab Lung cancer Amivantamab Atezolizumab IND Avelumab IND Brigatinib IND Capmatinib Cemiplimab Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. IND Cemiplimab wordt onderzocht als eerstelijns behandeling in combinatie met chemotherapie voor volwassen patiënten met lokaal gevorderd of gemetastaseerde plaveiselcel en niet-plaveiselcel NSCLC (stadium IIIB/C-IV) onafhankelijk van PD-L1 expressie. IND Durvalumab Non-small cell lung cancer (NSCLC) stage IV, in combination with tremelimumab and chemo,1L. Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. IND Imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). IND 1L advanced NSCLC IND Completely resected NSCLC IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) IND Ensartinib Entrectinib Lorlatinib IND Lurbinectedin Nivolumab IND Osimertinib IND Pralsetinib Selpercatinib Sotorasib Tedopi Tepotinib Trilaciclib Lymphoma Hypericin Mesothelioma Nivolumab IND Multiple Myeloma Belantamab mafodotin Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Multiple Myeloma 3L IND Carfilzomib IND Daratumumab Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). IND Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). IND Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. IND In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy. IND Subcutaneous formulation indicates for Relapsed or Refractory Multiple Myeloma. IND Multipel myeloom frontline behandeling in cpmbinatie met VRd voor patiënten die niet in aanmerking komen voor een ASCT. IND Multipel myeloom frontline onderhoudsbehandeling na DVTd, voor patiënten die in aanmerking komen voor een ASCT. IND Smouldering multipel myeloom. IND Idecabtagene vicleucel Isatuximab Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. IND In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. IND JNJ-4528 Lenalidomide IND Pomalidomide IND Selinexor Nexpovio is indicated in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. IND Myeloproliferative disorders Fedratinib Neuroendocrine cancer Selumetinib Surufatinib Other hematology Ibrutinib IND Zanubrutinib Other oncology 131I-omburtamab Dostarlimab Durvalumab IND Entrectinib Glucarpidase Ivosidenib IND Larotrectinib Lenvatinib IND Lipegfilgrastim IND NY-ESO-1 autologous engineered TCR-T cells Nivolumab Opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. IND Extension of indication to include adjuvant treatment of adult patients with resected oesophageal, or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy for OPDIVO. IND Pembrolizumab Keytruda as monotherapy is indicated for the first‑line treatment of metastatic microsatellite instability‑high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer in adults. IND Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. IND Keytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 10. IND Women With Persistent, Recurrent, or Metastatic Cervical Cancer (1L). IND Retifanlimab Selinexor IND Sodium thiosulfate Ovarian cancer Niraparib IND Olaparib IND Veliparib Pancreatic cancer Eryaspase (Asparaginase) Olaparib IND Prostate cancer 177Lu-PSMA-617 IND Abiraterone Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT); - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is ; - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. G Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT); - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is ; - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. G Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT); - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is ; - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. G Abiraterone / apalutamide Apalutamide IND Cabazitaxel G DCVAC Darolutamide Nubeqa is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Adult men with metastatic hormone senstive prostate cancer (mHSPC) in combination with docetaxel en ADT. IND Enzalutamide IND Masitinib Olaparib Monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. (only BRCA mutations included in the indication). IND Treatment in combination with abiraterone acetate in patients with metastatic Castration-resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting). IND Relugolix Skin cancer Atezolizumab IND Cemiplimab Monotherapy treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). IND Darleukin fibromun Lifileucel Relatlimab Seviprotimut-L Tavokinogene telseplasmid Stem cell transplants Inolimomab Itacitinib Motixafortide Narsoplimab Omidubicel Remestemcel-L Rimiducid Rivogenlecleucel Ruxolitinib IND Tabelecleucel Thiotepa G autologous anti-CD19-transduced CD3+ cells Stomach cancer Avapritinib Nivolumab IND Ripretinib Rivoceranib Trastuzumab deruxtecan IND Thyroid cancer Selpercatinib Patients With RET-Mutant Medullary Thyroid Cancer. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).